THE chief executive of listed medical technology company Medigard is in the US on a deal sealing mission for the company’s retractable syringe and blood collection device.
Peter Emery is aiming to lock down both a distributor and a manufacturer for the product.
“We’re locking the doors and putting all of our focus into securing these deals,” says Emery.
The company announced in December that it had entered a heads of agreement with a US medical device manufacturer.
“It has taken a while, but we are confident we have identified a good group of people. The timing now is critical. It is frustrating being in (the) medical devices industry, but people are very happy with our products and we continue to receive good feed back.”
Chairman Don Channer and director Peter Clark are majority shareholders of Medigard, owning 50 per cent between them.
MEDIGARD IN US TO SEAL DEAL
8 June 2010
Latest News
From $13,000 to $20 million: how a PCOS diagnosis and a pair of scissors built Xali Organics
Inspired by a medical diagnosis and driven by innovative marketing,...
Cedar Woods secures $63.4m in new land acquisitions as record presales underpin pipeline push
Perth-headquartered residential developer Cedar Woods Properties (A...
Australia's long-term beer decline hits home as Lion plans to close Boag's brewery in Launceston
Australia's decades-long decline in beer consumption has claime...
Downer EDI seals $310m Transurban contract to maintain Sydney motorway network
Infrastructure services group Downer EDI (ASX: DOW) has secured con...
Propel Funeral Partners expands New Zealand footprint with trio of acquisitions worth $9.1m
Sydney-based death care provider Propel Funeral Partners (ASX: PFP)...
Partner Content
For most Australian homeowners, the house gets the attention and the land gets taken fo...
Ventures & VisionariesAdvertisement

)

